GENFLEET-B (02595): As of November 6, a total of 2,907,800 H shares were repurchased.
GenFleet Therapeutics-B (02595) announced that as of November 6, 2026, the Company conducted a series of H share repurchases on The Stock Exchange of Hong Kong Limited, repurchasing a total of 2,907,800 H shares (Share Repurchases), representing approximately 0.757% of the total issued share capital of the Company as of the date of this announcement.
GENFLEET-B (02595) announced that as of November 6, 2026, the Company conducted a series of H share repurchases on The Stock Exchange of Hong Kong Limited, repurchasing a total of 2,907,800 H shares (the Share Repurchases), representing approximately 0.757% of the Company's total issued share capital as of the date of this announcement.
The Company may assess market conditions and continue to implement its 2026 H share repurchase plan.
Related Articles
SBP GROUP (01177): TQ-A3334 "TLR7 agonist" Phase II clinical data presented at 2026 AASLD
XTALPI (02228) Partners with LABORATOIRES PIERRE FABRE on AI-Driven Drug Discovery Collaboration
BEKE-W (02423) repurchased approximately 237,400 shares for about US$1.5 million on November 6.
SBP GROUP (01177): TQ-A3334 "TLR7 agonist" Phase II clinical data presented at 2026 AASLD
XTALPI (02228) Partners with LABORATOIRES PIERRE FABRE on AI-Driven Drug Discovery Collaboration
BEKE-W (02423) repurchased approximately 237,400 shares for about US$1.5 million on November 6.
